ProfileJobs

Bluebird Bio

Healthbiotechdrug developmentgeneticsoncology

Bluebird Bio is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include our LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy. Bluebird Bio programs in oncology are built upon its leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor and T cell receptor  T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. The Company also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across its pipeline.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
1992
Size (employees)
339 (est)+4%
Website
bluebirdbio.com
Bluebird Bio was founded in 1992 and is headquartered in Cambridge, US

Key People at Bluebird Bio

Nick Leschly

Nick Leschly

CEO
Jeffrey Walsh

Jeffrey Walsh

Chief Operating Officer

Bluebird Bio Office Locations

Bluebird Bio has offices in Cambridge and Seattle
Cambridge, US (HQ)
60 Binney St.
Seattle, US
208 1616 Eastlake Ave E

Bluebird Bio Data and Metrics

Bluebird Bio Financial Metrics

Bluebird Bio's revenue was reported to be $6.8 m in Q1, 2017
USD

Revenue (Q1, 2017)

6.8 m

Net income (Q1, 2017)

(68.7 m)

EBIT (Q1, 2017)

(69.9 m)

Market capitalization (25-Jul-2017)

4 b

Cash (31-Mar-2017)

216 m
Bluebird Bio's current market capitalization is $4 b.
USDFY, 2013Y, 2014Y, 2015FY, 2016

Revenue

20.2 m25.4 m14.1 m6.2 m

Revenue growth, %

26%(45%)(56%)

R&D expense

204.8 m

General and administrative expense

65.1 m

Operating expense total

45.1 m86 m183.1 m274 m

EBIT

(24.9 m)(60.6 m)(169 m)(267.8 m)

EBIT margin, %

(124%)(238%)(1201%)(4351%)

Interest income

29 k152 k

Pre tax profit

(60.5 m)(166.7 m)(264.1 m)

Income tax expense

(60 k)612 k

Net Income

(25.3 m)(48.7 m)(166.8 m)(263.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6.3 m6.4 m6.3 m4.9 m1.3 m1.5 m1.6 m1.6 m6.8 m

R&D expense

13.9 m16.6 m23.7 m44.3 m30.4 m41.9 m41.8 m64 m55 m

General and administrative expense

5.7 m6.6 m7.3 m10.7 m13.7 m16 m18.4 m14.6 m20.3 m

Operating expense total

19.7 m23.3 m31.1 m55 m44.1 m57.9 m60.1 m78.6 m75.3 m

EBIT

(13.3 m)(17 m)(24.9 m)(52 m)(43.1 m)(57.4 m)(60 m)(78.1 m)(69.9 m)

EBIT margin, %

(210%)(267%)(393%)(1053%)(3257%)(3828%)(3864%)(5035%)(1023%)

Pre tax profit

(13.3 m)(17 m)(51.8 m)(42.9 m)(56.4 m)(59.1 m)(77.2 m)(68.7 m)

Income tax expense

(60 k)145 k226 k178 k145 k

Net Income

(1.5 m)(17 m)(24.8 m)(51.8 m)(42.9 m)(56.3 m)(58.8 m)(77 m)(68.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

206.3 m347.8 m164.3 m278.9 m

Inventories

5 m4.5 m6 m19.8 m

Current Assets

212 m480 m524 m724.2 m

PP&E

10.9 m15.7 m82.6 m157 m

Goodwill

13.1 m13.1 m13.1 m

Total Assets

224.4 m556.7 m1 b1.1 b

Accounts Payable

4.4 m3 m6.3 m13.7 m

Current Liabilities

34.9 m43 m40.4 m74.5 m

Total Liabilities

248.7 m

Additional Paid-in Capital

250.1 m638.4 m1.2 b1.4 b

Retained Earnings

(98.7 m)(147.4 m)(314.2 m)(577.7 m)

Total Equity

151.7 m491.3 m850.5 m869.4 m

Financial Leverage

1.5 x1.1 x1.2 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

175.7 m89.6 m133.2 m593.3 m417.5 m192.6 m222.6 m245.2 m216 m

Current Assets

182.9 m223.3 m340.8 m815.5 m713.2 m561 m582.9 m608.8 m667.3 m

PP&E

12.9 m15 m16.9 m16.8 m61.6 m96.6 m109.3 m131.7 m181.7 m

Goodwill

13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m

Total Assets

240.6 m330.2 m533.8 m999.2 m1 b978.7 m941.7 m918.3 m1.1 b

Accounts Payable

2.6 m3.6 m2.6 m2.3 m3.5 m3.1 m2.4 m6.7 m8.8 m

Current Liabilities

39.5 m38.5 m42 m28 m33.6 m39 m40.4 m67.6 m72.6 m

Additional Paid-in Capital

276.3 m389.5 m646.5 m1.1 b1.2 b1.2 b1.2 b1.2 b1.5 b

Retained Earnings

(110.8 m)(127.8 m)(172.2 m)(224 m)(266.9 m)(370.4 m)(429.3 m)(506.3 m)(646.9 m)

Total Equity

165.8 m261.9 m474.5 m919 m889 m806.5 m759.3 m694.5 m815.4 m

Financial Leverage

1.5 x1.3 x1.1 x1.1 x1.1 x1.2 x1.2 x1.3 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(25.3 m)(48.7 m)(166.8 m)(263.5 m)

Depreciation and Amortization

941 k4.2 m7.4 m9.6 m

Inventories

(14 m)

Accounts Payable

2.1 m(2.2 m)2.5 m6.7 m

Cash From Operating Activities

43.5 m(59.7 m)(98.4 m)(189.6 m)

Purchases of PP&E

(8.7 m)(8.7 m)(7.1 m)(16 m)

Cash From Investing Activities

(9.8 m)(157.2 m)(571.9 m)62.7 m

Cash From Financing Activities

105.6 m358.5 m486.7 m241.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.5 m)(17 m)(24.8 m)(51.8 m)(42.9 m)(56.3 m)(58.8 m)(77 m)(68.7 m)

Accounts Payable

2.6 m3.6 m2.6 m2.3 m3.5 m3.1 m2.4 m6.7 m8.8 m
USDY, 2017

Revenue/Employee

20.5 k

Financial Leverage

1.3 x

Bluebird Bio Market Value History

Bluebird Bio Median Salaries

Source: 16 public H-1B filings from Bluebird Bio

Market Position of Bluebird Bio

Competitors

Dicerna Pharmaceuticals
Health - Public
LAM Therapeutics
Health - Private
ImmunoGen
Health - Public
Heat Biologics
Health - Public
Compare competitors

Bluebird Bio Online and Social Media Presence

Bluebird Bio News and Updates

Bluebird Bio Company Life and Culture

You may also be interested in